Bain Capital Private Equity and Cinven enter into definitive agreements to acquire Lonza Specialty Ingredients

On February 8, 2021, Bain Capital Private Equity and Cinven have entered into definitive agreements to acquire Lonza Specialty Ingredients (“LSI”), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. The transaction is expected to close in the second half of 2021, subject to customary closing conditions.

Headquartered in Basel, LSI has approximately 2,800 employees, 11 R&D centres and 17 manufacturing sites across the world. LSI is a world-leading provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. The business also produces a range of other specialty chemicals, centred around its unique production facility in Switzerland. The business serves approx. 5,300 customers across a wide range of end-markets.

Lenz & Staehelin advises Bain Capital Private Equity and Cinven on this transaction.